{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:32:13Z","timestamp":1793140333266,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"publisher","award":["Public Health Talent Grant (Global Health Governance-02-12)"],"award-info":[{"award-number":["Public Health Talent Grant (Global Health Governance-02-12)"]}],"id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001547","name":"China Medical Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574167"],"award-info":[{"award-number":["82574167"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404326"],"award-info":[{"award-number":["82404326"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472266"],"award-info":[{"award-number":["82472266"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","award":["National Excellent Young Physician Project"],"award-info":[{"award-number":["National Excellent Young Physician Project"]}],"id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2306700"],"award-info":[{"award-number":["2023YFC2306700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2308302"],"award-info":[{"award-number":["2023YFC2308302"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFE0116000"],"award-info":[{"award-number":["2023YFE0116000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2304900"],"award-info":[{"award-number":["2022YFC2304900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2308300"],"award-info":[{"award-number":["2023YFC2308300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018536","name":"National Mega Project on Major Infectious Disease Prevention","doi-asserted-by":"publisher","award":["2025ZD01905200"],"award-info":[{"award-number":["2025ZD01905200"]}],"id":[{"id":"10.13039\/501100018536","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010227","name":"Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau","doi-asserted-by":"publisher","award":["ZKX22040"],"award-info":[{"award-number":["ZKX22040"]}],"id":[{"id":"10.13039\/501100010227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI121259"],"award-info":[{"award-number":["R01 AI121259"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eclinm.2026.104189","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:56:03Z","timestamp":1788468963000},"page":"104189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-acting HIV pre-exposure prophylaxis adherence and discontinuation: a global systematic review and meta-analysis"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5905-8788","authenticated-orcid":false,"given":"Xinyue","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0852-7291","authenticated-orcid":false,"given":"Thomas S.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Bavinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nittaya","family":"Phanuphak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-4460","authenticated-orcid":false,"given":"Hongbo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rugang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianguo","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maohe","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-0108","authenticated-orcid":false,"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengliang","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7604-5139","authenticated-orcid":false,"given":"Yinzhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5140-0440","authenticated-orcid":false,"given":"Bin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8161-7576","authenticated-orcid":false,"given":"Huachun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.eclinm.2026.104189_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"10337","key":"10.1016\/j.eclinm.2026.104189_bib2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104189_bib3","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/17425247.2022.2135699","article-title":"Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges","volume":"19","author":"Agrahari","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"issue":"27","key":"10.1016\/j.eclinm.2026.104189_bib4","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104189_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104189_bib6","series-title":"Conference on Retroviruses and Opportunistic Infections 2026","article-title":"Twice-yearly subcutaneous lenacapavir for PrEP: updated HIV-1 incidence & safety data in PURPOSE 1 at the end of the randomized blinded phase","author":"Ndlovu","year":"2026"},{"key":"10.1016\/j.eclinm.2026.104189_bib7","series-title":"Conference on Retroviruses and Opportunistic Infections 2026","article-title":"Lenacapavir for PrEP: HIV-1 incidence and safety from PURPOSE 2 at the end of randomized blinded phase","author":"Cantos","year":"2026"},{"issue":"13","key":"10.1016\/j.eclinm.2026.104189_bib8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"Kelley","year":"2025","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.eclinm.2026.104189_bib9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104189_bib11","series-title":"PRISMA 2020 checklist","year":"2020"},{"key":"10.1016\/j.eclinm.2026.104189_bib12","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2024"},{"key":"10.1016\/j.eclinm.2026.104189_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100303","article-title":"Safety and tolerability of injectable Rilpivirine LA in HPTN 076: a phase 2 HIV pre-exposure prophylaxis study in women","volume":"21","author":"Bekker","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"22","key":"10.1016\/j.eclinm.2026.104189_bib14","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"Baeten","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104189_bib15","series-title":"2025 global AIDS update \u2014 AIDS, crisis and the power to transform","year":"2025"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104189_bib16","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/sim.10008","article-title":"Sensitivity analysis with iterative outlier detection for systematic reviews and meta-analyses","volume":"43","author":"Meng","year":"2024","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2026.104189_bib17","series-title":"Quality assessment tool for quantitative studies","year":"2004"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104189_bib18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/clpt.2014.118","article-title":"A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis","volume":"96","author":"Jackson","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104189_bib19","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s10461-020-02808-2","article-title":"Acceptability of long-acting injectable Cabotegravir (CAB LA) in HIV-Uninfected individuals: HPTN 077","volume":"24","author":"Tolley","year":"2020","journal-title":"AIDS Behav"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104189_bib20","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1089\/aid.2018.0265","article-title":"A multiple dose phase 1 assessment of rilpivirine long acting in a model of preexposure prophylaxis against HIV","volume":"35","author":"Cranston","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104189_bib21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/cid\/ciae531","article-title":"High retention and adherence with rapid long-acting injectable pre-exposure prophylaxis implementation in an urban safety net clinic population","volume":"80","author":"Spinelli","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104189_bib22","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1016\/S2352-3018(16)30113-8","article-title":"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment","volume":"3","author":"McGowan","year":"2016","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104189_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11606-025-09350-8","article-title":"Early implementation of long-acting injectable cabotegravir for HIV prevention in a safety net hospital-based primary care Center in U.S. South","volume":"41","author":"Baker","year":"2026","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.eclinm.2026.104189_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad500.1366","article-title":"Early real-world experience of long-acting Cabotegravir (CAB) for HIV pre-exposure prophylaxis (PrEP) in a large Community-Based Clinic Network (CAN community health): utilization and PrEP persistence","volume":"10","author":"Altamirano","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.eclinm.2026.104189_bib25","series-title":"Conference on retroviruses and opportunistic infections","article-title":"ImPrEP CAB Brasil: enhancing PrEP coverage with CAB-LA in young key populations","author":"Grinsztejn","year":"2025"},{"key":"10.1016\/j.eclinm.2026.104189_bib26","series-title":"International Antiviral Society-USA (IAS-USA)","article-title":"PILLAR month 12 clinical results: zero HIV acquisition and high persistence with CAB LA for PrEP","author":"Khan","year":"2025"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104189_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0000000000003396","article-title":"Feasibility of implementing a low-barrier long-acting injectable antiretroviral program for HIV treatment and prevention for people experiencing homelessness","volume":"96","author":"Mehtani","year":"2024","journal-title":"J Acq Immune Defic Syndr"},{"issue":"Supplement_1","key":"10.1016\/j.eclinm.2026.104189_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.157","article-title":"Real-world use of Cabotegravir long-acting for pre-exposure prophylaxis: data from Trio Health cohort","volume":"12","author":"Ramgopal","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.eclinm.2026.104189_bib29","series-title":"12th IAS conference on HIV science","article-title":"Feasibility of long-acting injectable Cabotegravir PrEP initiation and administration by Community Health workers and early aspects of the PrEP injection care continuum in a primary care Center in Washington, D.C","author":"Patel","year":"2023"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104189_bib30","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/QAI.0000000000003889","article-title":"Long-acting injectable cabotegravir HIV PrEP uptake, adherence, and persistence in two large US integrated healthcare systems","volume":"101","author":"Traeger","year":"2026","journal-title":"J Acq Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104189_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/OLQ.0000000000002272","article-title":"Patterns and correlates of initiation of long-acting injectable cabotegravir for preexposure prophylaxis: a case-control analysis","volume":"53","author":"Rossotti","year":"2026","journal-title":"Sex Transm Dis"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104189_bib32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/hiv.70162","article-title":"User-reported outcomes of long-acting injectable PrEP with Cabotegravir: real-world experience from Milan","volume":"27","author":"Raccagni","year":"2026","journal-title":"HIV Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104189_bib33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/QAI.0000000000002820","article-title":"Genital mucosal drug concentrations and anti-HIV activity in Tenofovir-based PrEP products: intravaginal ring vs. oral administration","volume":"89","author":"Ouattara","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104189_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304552","article-title":"Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings","volume":"19","author":"Achilles","year":"2024","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104189_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002655","article-title":"Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: a phase I trial","volume":"15","author":"Vincent","year":"2018","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104189_bib36","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/ciy654","article-title":"Phase 2a safety, pharmacokinetics, and acceptability of dapivirine vaginal rings in US postmenopausal women","volume":"68","author":"Chen","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2026.104189_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/frph.2023.1118030","article-title":"Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya","volume":"5","author":"Mugo","year":"2023","journal-title":"Front Reprod Health"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104189_bib38","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1016\/S2352-3018(23)00227-8","article-title":"Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial","volume":"10","author":"Nair","year":"2023","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104189_bib39","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3018(20)30304-0","article-title":"Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study","volume":"8","author":"Baeten","year":"2021","journal-title":"Lancet HIV"},{"issue":"22","key":"10.1016\/j.eclinm.2026.104189_bib40","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104189_bib41","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S2352-3018(20)30300-3","article-title":"Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study","volume":"8","author":"Nel","year":"2021","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104189_bib42","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2352-3018(24)00306-0","article-title":"Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial","volume":"12","author":"Noguchi","year":"2025","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104189_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0312957","article-title":"Acceptability of a dapivirine levonorgestrel vaginal ring in two phase 1 trials (MTN-030\/IPM 041 and MTN-044\/IPM 053\/CCN019): implications for multipurpose prevention technology development","volume":"20","author":"Friedland","year":"2025","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104189_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25283","article-title":"End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study","volume":"22","author":"Montgomery","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2026.104189_bib45","article-title":"User and healthcare provider early experiences with the PrEP ring: a quantitative study on the introduction of a new PrEP method in Eswatini","volume":"28","author":"Hettema","year":"2025","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.eclinm.2026.104189_bib46","series-title":"2024 conference on retroviruses and opportunistic infections (CROI)","article-title":"Insurance type drives Cabotegravir delays: real-world long-acting PrEP outcomes in the midwest US","author":"Hazra","year":"2024"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2026.104189_bib47","article-title":"Feasibility and acceptability of persons on long-acting cabotegravir for HIV prevention in the SEARCH dynamic choice HIV prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study","volume":"28","author":"Kakande","year":"2025","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104189_bib48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.52403\/ijhsr.20250725","article-title":"Survival of individuals on long-acting Cabotegravir injection for HIV pre-exposure prophylaxis in Zambia: a retrospective cohort study","volume":"15","author":"Kawanga","year":"2025","journal-title":"Int J Health Sci Res"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104189_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002690","article-title":"Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial","volume":"15","author":"Landovitz","year":"2018","journal-title":"PLoS Med"},{"issue":"Supplement_1","key":"10.1016\/j.eclinm.2026.104189_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.160","article-title":"Cabotegravir long-acting for pre-exposure prophylaxis (PrEP): real world data on On-Time dosing, HIV testing and HIV acquisition from the OPERA cohort","volume":"12","author":"Mills","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"39","key":"10.1016\/j.eclinm.2026.104189_bib51","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.39.2500739","article-title":"Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025","volume":"30","author":"Moschese","year":"2025","journal-title":"Euro Surveill"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104189_bib52","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2352-3018(24)00310-2","article-title":"Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial","volume":"12","author":"Stranix-Chibanda","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eclinm.2026.104189_bib53","series-title":"5th HIV Research for Prevention Conference (HIVR4P 2024)","article-title":"Implementing long-acting cabotegravir for HIV pre-exposure prophylaxis in a large academic hospital-based Urban HIV clinic","author":"Turner","year":"2024"},{"issue":"S2","key":"10.1016\/j.eclinm.2026.104189_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26492","article-title":"PrEP preferences and early acceptability of injectable cabotegravir among pregnant and lactating people in Cape Town, South Africa: findings from the PrEPared to choose study","volume":"28","author":"Wara","year":"2025","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2026.104189_bib55","article-title":"PrEP choice in the real world: results of a prospective cohort study describing uptake and use patterns of oral PrEP and the dapivirine vaginal ring among women in sub-Saharan Africa","volume":"28","author":"Fonner","year":"2025","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104189_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jadohealth.2021.04.001","article-title":"Adherence to pre-exposure prophylaxis in adolescents and young adults: a systematic review and meta-analysis","volume":"70","author":"Allison","year":"2022","journal-title":"J Adolesc Health"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104189_bib57","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","article-title":"Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eclinm.2026.104189_bib58","author":"Aziz"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104189_bib59","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1186\/s12879-023-08693-z","article-title":"Demand creation and retention strategies for oral pre-exposure prophylaxis for HIV prevention among men who have sex with men and transgender women: a systematic review and meta-analysis","volume":"23","author":"Guimar\u00e3es","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104189_bib60","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/JNC.0000000000000460","article-title":"A systematic review of oral pre-exposure prophylaxis HIV adherence interventions","volume":"35","author":"Haines","year":"2024","journal-title":"J Assoc Nurses AIDS Care"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104189_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048478","article-title":"Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations","volume":"12","author":"O Murchu","year":"2022","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104189_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf539","article-title":"HIV oral pre-exposure prophylaxis effectiveness, adherence, and discontinuation in an Italian multicentric access Program: ItaPrEP Study","volume":"12","author":"Mazzotta","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104189_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11904-024-00715-y","article-title":"Understanding the drivers of CAB PrEP uptake and use among women in Sub-Saharan Africa to build demand for new PrEP methods","volume":"22","author":"Bishopp","year":"2024","journal-title":"Curr HIV AIDS Rep"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104189_bib64","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s12879-025-10871-0","article-title":"Bridging the gap: identifying barriers and strategies for widespread implementation of long-acting injectable antiretroviral therapy in Sub-Saharan Africa: a scoping review","volume":"25","author":"Gashema","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104189_bib65","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1186\/s12905-024-03516-y","article-title":"Barriers to PrEP use and adherence among adolescent girls and young women in Eastern, Southern, and Western Africa: a scoping review","volume":"24","author":"Admassu","year":"2024","journal-title":"BMC Womens Health"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2026.104189_bib66","article-title":"\u201cPeople have options\u201d: a qualitative study of experiences and influences of PrEP choice among women in South Africa","volume":"28 Suppl 2","author":"Dada","year":"2025","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104189_bib67","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/QAD.0000000000001868","article-title":"Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results","volume":"32","author":"Montgomery","year":"2018","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104189_bib68","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1186\/s12889-024-18795-1","article-title":"Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring study (IPM 027)","volume":"24","author":"Milford","year":"2024","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104189_bib69","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/QAI.0000000000003756","article-title":"Higher acceptability of the monthly dapivirine ring versus daily oral pre-exposure prophylaxis among adolescent girls and young women in Sub-Saharan Africa in the REACH trial","volume":"100","author":"Friedland","year":"2025","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:32:49Z","timestamp":1793136769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026004426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":68,"alternative-id":["S2589537026004426"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104189","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-acting HIV pre-exposure prophylaxis adherence and discontinuation: a global systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104189"}}